Home > Boards > US Listed > Biotechs > Verastem (VSTM)

Seems Management has more faith in the company

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
 
Followed By 16
Posts 1,195
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2019 5:12:40 PM
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on... Business Wire - 6/21/2019 7:00:00 AM
Verastem Oncology Announces Leadership Changes Business Wire - 6/20/2019 7:00:00 AM
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting Business Wire - 6/17/2019 7:00:00 AM
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference Business Wire - 5/30/2019 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/20/2019 5:23:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:22:02 PM
Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference Business Wire - 5/16/2019 7:00:00 AM
Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study Business Wire - 5/15/2019 5:16:00 PM
Verastem Oncology Reports First Quarter 2019 Financial Results Business Wire - 5/9/2019 4:05:00 PM
Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019 Business Wire - 5/2/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2019 4:22:15 PM
Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility Business Wire - 4/23/2019 4:05:00 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/8/2019 4:13:23 PM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 4/4/2019 4:05:00 PM
Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire - 4/2/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/19/2019 4:14:21 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/18/2019 6:10:17 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/12/2019 4:28:34 PM
Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments Business Wire - 3/12/2019 4:08:00 PM
Verastem Oncology to Present at Upcoming Investor Conferences Business Wire - 3/12/2019 7:00:00 AM
Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Mali... Business Wire - 3/7/2019 5:01:00 PM
Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) in Patients with CLL/SLL Who Have Progresse... Business Wire - 3/4/2019 7:00:00 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 3/1/2019 4:49:00 PM
Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019 Business Wire - 2/26/2019 7:00:00 AM
stockguard   Wednesday, 02/20/19 05:19:24 PM
Re: None
Post # of 405 
Seems Management has more faith in the company than does the market. The years i've owned/traded $VSTM, Management has not disappointed yet.

Verastem Oncology Announces Key Management Appointments

“Verastem Oncology continues to grow our operations across the U.S. in crucial functional areas, such as commercial management, clinical development, medical affairs, regulatory, quality assurance and investor relations and communications,” said Robert Forrester, President and Chief Executive Officer of Verastem Oncology. “We are delighted to welcome Amy, Bob and Erin to our team to support us in our mission of bringing new cancer therapies to patients and families battling these devastating diseases. We will greatly benefit from Amy’s successful product launch expertise and deep knowledge of the b-cell malignancies space. Bob is also an important addition that will help guide the organization and advancement of our pipeline of therapies to late-stage development. Erin’s extensive IR and communications experience in the biotechnology industry will be critical as we continue to increase our presence within the financial community.”

https://seekingalpha.com/pr/17417540-correcting-replacing-verastem-oncology-announces-key-management-appointments

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist